Kolbe, C., Kauer, J., Brinkmann, B., Dreger, P., Huber, W., Müller-Tidow, C., Dietrich, S., Roider, T.

Bispecific antibodies (BsAb) have emerged as a leading treatment modality in patients suffering from B-cell non-Hodgkin’s lymphoma (B-NHL). However, treatment failure is common and may potentially be attributed to pre-existing or emerging T-cell…